SciSparc and Clearmind’s collaboration continues to yield positive outcomes, the latest with Clearmind results for treating obesity and its related…
The non- clinical study was conducted at The Chaim Sheba Medical Center in Israel Tel-Aviv, Dec. 07, 2022 (GLOBE NEWSWIRE)…
Tel-Aviv, Nov. 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development…
DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid…
-Agreement Provides Flexible Funding on Path to NDA Submission for PAX-101- TARRYTOWN, NY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via…
Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing…
Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million…
ALA-002 is PharmAla’s lead drug candidate, showing exceptional safety and efficacy in preclinical rodent modelsVANCOUVER, British Columbia, Nov. 02, 2022…
Agreement is expected to optimize handling and shipment processes and reduce direct sales costs TEL AVIV, Israel, Nov. 01, 2022…
WOBURN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted,…